FI114154B - Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi Download PDF

Info

Publication number
FI114154B
FI114154B FI960101A FI960101A FI114154B FI 114154 B FI114154 B FI 114154B FI 960101 A FI960101 A FI 960101A FI 960101 A FI960101 A FI 960101A FI 114154 B FI114154 B FI 114154B
Authority
FI
Finland
Prior art keywords
magnesium
omeprazole
process according
determined
crystals
Prior art date
Application number
FI960101A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI960101A0 (fi
FI960101A (fi
Inventor
Lars Aake Kaellstroem
Monica Annelie Nygren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI114154(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI960101A0 publication Critical patent/FI960101A0/fi
Publication of FI960101A publication Critical patent/FI960101A/fi
Application granted granted Critical
Publication of FI114154B publication Critical patent/FI114154B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
FI960101A 1993-07-09 1996-01-09 Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi FI114154B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE19939302396A SE9302396D0 (sv) 1993-07-09 1993-07-09 A novel compound form
SE9302396 1993-07-09
PCT/SE1994/000680 WO1995001977A1 (en) 1993-07-09 1994-07-08 Magnesium omeprazole
SE9400680 1994-07-08

Publications (3)

Publication Number Publication Date
FI960101A0 FI960101A0 (fi) 1996-01-09
FI960101A FI960101A (fi) 1996-01-09
FI114154B true FI114154B (fi) 2004-08-31

Family

ID=20390588

Family Applications (1)

Application Number Title Priority Date Filing Date
FI960101A FI114154B (fi) 1993-07-09 1996-01-09 Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi

Country Status (42)

Country Link
US (1) US5900424A (de)
EP (2) EP0707580B1 (de)
JP (2) JP3635432B2 (de)
KR (1) KR100353783B1 (de)
CN (1) CN1064680C (de)
AT (1) ATE212628T1 (de)
AU (1) AU679766B2 (de)
BR (1) BR9406940A (de)
CA (1) CA2166794C (de)
CZ (1) CZ288933B6 (de)
DE (2) DE69429774T2 (de)
DK (1) DK0707580T3 (de)
DZ (1) DZ1792A1 (de)
EE (1) EE03127B1 (de)
EG (1) EG21437A (de)
ES (1) ES2100136T3 (de)
FI (1) FI114154B (de)
GR (1) GR970300015T1 (de)
HK (1) HK1008329A1 (de)
HR (1) HRP940385B1 (de)
HU (1) HU226861B1 (de)
IL (1) IL110190A (de)
IS (1) IS2075B (de)
MA (1) MA23257A1 (de)
MX (1) MX9405217A (de)
MY (1) MY113274A (de)
NO (1) NO308702B1 (de)
NZ (1) NZ268693A (de)
PL (1) PL175999B1 (de)
PT (1) PT707580E (de)
RU (1) RU2139868C1 (de)
SA (1) SA94150058B1 (de)
SE (1) SE9302396D0 (de)
SG (1) SG52464A1 (de)
SI (1) SI0707580T1 (de)
SK (1) SK281230B6 (de)
TN (1) TNSN94079A1 (de)
TW (1) TW504509B (de)
UA (1) UA43343C2 (de)
WO (1) WO1995001977A1 (de)
YU (1) YU49193B (de)
ZA (1) ZA944933B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
MX9700152A (es) * 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
JP3350054B2 (ja) 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) * 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
US6623759B2 (en) 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6048981A (en) * 1998-04-22 2000-04-11 Torcan Chemical Ltd. Magnesium omeprazole and process for its preparation
DE19843413C1 (de) 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
UA72748C2 (en) 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
IL142703A (en) * 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
NZ511169A (en) * 1998-11-18 2003-06-30 Astrazeneca Ab Process for making substituted sulphinyl heterocycles containing an imidazole moiety
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
US6316020B1 (en) * 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
CA2290893C (en) * 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
WO2001087831A2 (en) * 2000-05-15 2001-11-22 Ranbaxy Laboratories Limited Novel amorphous form of omeprazole salts
CA2386716C (en) * 2002-05-17 2012-07-24 Bernard Charles Sherman Magnesium salt of s-omeprazole
JP5412023B2 (ja) 2000-08-04 2014-02-12 武田薬品工業株式会社 ベンズイミダゾール化合物の塩およびその用途
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2472103A1 (en) * 2002-01-25 2003-08-07 Santarus, Inc. Transmucosal delivery of proton pump inhibitors
FR2836228B1 (fr) * 2002-02-21 2005-08-19 Inst Francais Du Petrole Methode et dispositif pour evaluer des parametres physiques d'un gisement souterrain a partir de debris de roche qui y sont preleves
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1633736A1 (de) * 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salz eines benzimidazol-derivats
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
JP4919801B2 (ja) 2003-09-26 2012-04-18 アルザ・コーポレーシヨン 高い薬剤配合量を提供する薬剤コーティング及びそれを提供する方法
WO2005082888A1 (en) * 2004-03-01 2005-09-09 Milen Merkez Ilac Endustrisi A.S. Process for the preparation of magnesium salt of omeprazole
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006067599A2 (en) 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
US20060160783A1 (en) * 2004-12-30 2006-07-20 Transform Pharmaceuticals, Inc. Novel omeprazole forms and related methods
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1801110A1 (de) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Argininsalz des Esomeprazols
US7553857B2 (en) 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
DK2046334T3 (da) 2006-07-25 2014-08-25 Vecta Ltd Sammensætninger og fremgangsmåder til at hæmme mavesyresekretion ved at anvende derivater af små dicarboxylsyrer i kombination med PPI
EP2068841B1 (de) 2006-10-05 2018-09-26 Santarus, Inc. Neuartige formulierungen von protonenpumpenhemmern und verfahren zu ihrer verwendung
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EP1947099A1 (de) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Verfahren zur Entfernung von Lösungsmitteln in Omeprazol-Salzen
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
CN102015704A (zh) 2008-04-29 2011-04-13 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2147918A1 (de) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Verfahren zur Herstellung von S-Omeprazol-Magnesium in einer stabilen Form
EP2344139A1 (de) * 2008-09-09 2011-07-20 AstraZeneca AB Verfahren zur abgabe einer pharmazeutischen zusammensetzung an einen patienten, der diese benötigt
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (de) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Säurelabile Arzneimittelformulierungen
EP2601947A1 (de) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Kombinationspräparat mit fester Dosierung zur Behandlung von Erkrankungen einhergehend mit Helicobacter pylori
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form

Also Published As

Publication number Publication date
FI960101A0 (fi) 1996-01-09
DE69429774T2 (de) 2002-11-14
CN1126993A (zh) 1996-07-17
MA23257A1 (fr) 1995-04-01
EP0707580A1 (de) 1996-04-24
NO308702B1 (no) 2000-10-16
DE69429774D1 (de) 2002-03-14
JP3635432B2 (ja) 2005-04-06
CA2166794C (en) 1997-03-04
JP2002105072A (ja) 2002-04-10
HU9503873D0 (en) 1996-02-28
PL175999B1 (pl) 1999-03-31
NO960068D0 (no) 1996-01-05
ES2100136T3 (es) 2002-09-01
AU679766B2 (en) 1997-07-10
DZ1792A1 (fr) 2002-02-17
ATE212628T1 (de) 2002-02-15
NZ268693A (en) 1997-05-26
UA43343C2 (uk) 2001-12-17
KR100353783B1 (ko) 2004-04-03
US5900424A (en) 1999-05-04
SK2296A3 (en) 1996-10-02
SK281230B6 (sk) 2001-01-18
IS2075B (is) 2005-12-15
SA94150058B1 (ar) 2006-06-20
JPH08512315A (ja) 1996-12-24
HUT75314A (en) 1997-05-28
HK1008329A1 (en) 1999-05-07
ZA944933B (en) 1995-02-20
CN1064680C (zh) 2001-04-18
SI0707580T1 (en) 2002-06-30
DK0707580T3 (da) 2002-04-15
MY113274A (en) 2002-01-31
YU43694A (sh) 1997-07-31
CZ288933B6 (cs) 2001-09-12
PT707580E (pt) 2002-06-28
HU226861B1 (en) 2009-12-28
SG52464A1 (en) 1998-09-28
EP0707580B1 (de) 2002-01-30
DE707580T1 (de) 1997-09-04
HRP940385A2 (en) 1997-02-28
BR9406940A (pt) 1996-09-10
NO960068L (no) 1996-01-05
TW504509B (en) 2002-10-01
IS4186A (is) 1995-01-10
GR970300015T1 (en) 1997-05-31
WO1995001977A1 (en) 1995-01-19
AU7198194A (en) 1995-02-06
IL110190A (en) 2000-07-26
CZ6996A3 (en) 1996-05-15
HRP940385B1 (en) 2003-06-30
JP3878826B2 (ja) 2007-02-07
SE9302396D0 (sv) 1993-07-09
YU49193B (sh) 2004-09-03
ES2100136T1 (es) 1997-06-16
TNSN94079A1 (fr) 1995-04-25
MX9405217A (es) 1995-01-31
IL110190A0 (en) 1994-10-21
EG21437A (en) 2001-10-31
FI960101A (fi) 1996-01-09
EP1164132A3 (de) 2002-01-02
PL312440A1 (en) 1996-04-29
EE03127B1 (et) 1998-10-15
EP1164132A2 (de) 2001-12-19
RU2139868C1 (ru) 1999-10-20

Similar Documents

Publication Publication Date Title
FI114154B (fi) Menetelmä terapeuttisesti käyttökelpoisen magnesiumomepratsolin valmistamiseksi
WO1995001977A9 (en) Magnesium omeprazole
FI91263B (fi) Menetelmä atsitromysiinidihydraatin valmistamiseksi
CA2521391C (en) Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate
CS274420B2 (en) Method of clock-wise isomer alpha-(4,5,6,7-tetrahydrothieno (3,2-c)-5-pyridyl)-)2-chlorphenyl) methylacetate production
JP2006504618A (ja) 非結晶性及び結晶性ロサルタン・カリウム、及びそれらの調製方法
KR100774271B1 (ko) 발라사이클로비르 염산염의 결정질 형태
NO317304B1 (no) Tetrahydropyridoetere
RU2088584C1 (ru) Кристаллический полугидрат 4-(5,6,7,8-тетрагидроимидазо [1,5-а]пиридин-5-ил)-бензонитрил-гидрохлорида
KR20030042038A (ko) 온단세트론 히드로클로라이드의 신규한 결정 형태 및용매화물 형태와 이들의 제조 방법
WO2000078729A1 (en) Crystalline forms of lansoprazole
JPS5953493A (ja) 新規なチエノ−チアゾ−ル誘導体
SU1279530A3 (ru) Способ получени замещенных пиррол или пиридо /2,1- @ / хиназолинов или их солей
JPH06192228A (ja) 結晶性（ｒ）−（−）−２−シクロヘプチル−ｎ−メチルスルフオニル−［４−（２−キノリニルメトキシ）−フエニル］−アセトアミド
JPS604189B2 (ja) 抗菌剤およびその製法
US4094988A (en) Method of treating gastric ulcers using 5,6-dihydro-1,4-dithiinoxides
CH644375A5 (fr) Pyridylaminotriazoles et composition pharmaceutique les contenant.
JPH08239381A (ja) 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
FR2523972A1 (fr) Derives vinyliques substitues de la 1h-pyrazolo-(1,5-a) pyrimidine utiles notamment comme medicaments antiulcerigenes et antisecretoires gastriques et procede de leur preparation
TW200827357A (en) Improved process for the manufacture of mirtazapine
CN116143709A (zh) 丹酚酸a衍生物的新晶型及其制备方法
MXPA01004794A (en) Crystalline forms of 3-(2, 4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide

Legal Events

Date Code Title Description
MA Patent expired